CURE’s lung cancer page is an extensive resource of cancer information featuring the latest lung cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on lung cancer.
April 29th 2025
The Ventana TROP2 RxDx Device, a computational companion diagnostic, was granted breakthrough device designation by the FDA in non–small cell lung cancer.
Frontline Tagrisso Granted Priority Review for Lung Cancer Treatment
December 18th 2017Frontline Tagrisso (osimertinib) was granted a priority review to a supplemental new drug application (sNDA) by the Food and Drug Administration (FDA) to treat patients with non-small cell lung cancer (NSCLC) whose tumors have EGFR mutations (exon 19 deletions or exon 21 [L858R] substitution mutations).
Frontline Alecensa Approved for Lung Cancer Treatment
November 7th 2017Alecensa (alectinib) was granted approval by the Food and Drug Administration (FDA) to treat patients with ALK-positive metastatic non–small cell lung cancer (NSCLC), according to Genentech (Roche), the manufacturer of the second-generation ALK inhibitor.
Keytruda Approved for Lung Cancer
October 3rd 2015The PD-1 inhibitor was approved along with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, and is indicated for patients who progressed on or after platinum-containing chemotherapy or EGFR- or ALK-targeted agents in patients harboring those mutations.
Carolyn Presley Discusses the Burden of Curative Lung Cancer Treatment
October 3rd 2015Carolyn Presley, clinical fellow, geriatric oncology, Yale Cancer Center, Robert Wood Johnson Clinical Scholar, discusses a study looking at the burden of health care on patients undergoing curative lung cancer care.